Sidley, Mintz Guide Gene Biz Acquisition Worth Up To $7M
Cell therapy specialist MaxCyte said Thursday that it has bought gene editing company SeQure Dx in a deal worth up to $7 million as it seeks to strengthen its ability to help...To view the full article, register now.
Already a subscriber? Click here to view full article